Notis Global (NGBL) 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 10, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	MDBX
Entity Registrant Name	Medbox, Inc.
Entity Central Index Key	1,547,996
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		69,823,415

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 564,267	$ 101,182
Marketable securities	94,817	94,776
Accounts receivable		8,774
Inventory, net of valuation reserve of $293,473	377,663	961,236
Deposits in escrow	90,000	400,476
Prepaid insurance	370,366	31,491
Prepaid expenses and other current assets	153,159	34,729
Total current assets	1,650,272	1,632,664
Property and equipment, net of accumulated depreciation of $40,763 and $50,192, respectively	115,722	158,318
Assets held for resale	399,594	399,594
Intangible assets, net of accumulated amortization of $109,584 and $83,500 respectively	683,069	709,153
Note receivable, net of allowance of $350,000	0	0
Goodwill	1,260,037	1,260,037
Deferred Costs	299,018
Deposits and other assets	172,212	104,726
Total assets	4,579,924	4,264,492
Current liabilities
Accounts payables	2,799,533	1,713,627
Accrued interest payable	247,930	372,937
Accrued expenses	122,362	610,497
Accrued settlement and severance expenses	1,004,486
Deferred revenue, current	196,884	204,091
Notes payable	249,000	261,434
Related party notes payable	474,888	678,877
Convertible notes payable, net of discount of $0 and $1,225,573, respectively	4,655,701	2,524,427
Convertible notes payable, related parties	150,000
Derivative Liability	2,047,673	3,691,853
Customer deposits	1,214,808	1,525,808
Total current liabilities	13,163,265	11,583,551
Deferred revenue, less current portion	524,418	568,515
Deferred tax liability	160,000	160,000
Total liabilities	$ 13,847,683	$ 12,312,066
Commitments and contingencies (see Note 9)
Stockholders' Equity/(Deficit)
Preferred stock, $0.001 par value: 10,000,000 authorized; 3,000,000 and 3,000,000 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	$ 3,000	$ 3,000
Common stock, $0.001 par value: 100,000,000 authorized, 44,273,535 and 30,496,909 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	44,274	30,497
Additional paid-in capital	29,909,695	15,315,110
Treasury stock	(1,209,600)	(1,209,600)
Accumulated deficit	(37,906,780)	(22,078,193)
Accumulated other comprehensive loss	(108,348)	(108,388)
Total stockholders' deficit	(9,267,759)	(8,047,574)
Total liabilities and stockholders' deficit	$ 4,579,924	$ 4,264,492

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Inventory, valuation reserve	$ 293,473
Property and equipment, accumulated depreciation (in Dollars)	40,763	$ 50,192
Intangible assets, accumulated amortization (in Dollars)	109,584	83,500
Note receivable, allowance	350,000
Convertible notes payable, discount	$ 0	$ 1,225,573
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	3,000,000	3,000,000
Preferred stock, outstanding	3,000,000	3,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	44,273,535	30,496,909
Common stock, outstanding	44,273,535	30,496,909

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 59,447	$ 335,187	$ 101,195	$ 386,197
Revenue, related party	24,918	24,918	49,562	24,918
Less: allowances and refunds				(60,000)
Net revenue	84,365	360,105	150,757	351,115
Cost of revenues	867,025	728,669	1,181,328	1,678,542
Gross loss	(782,660)	(368,564)	(1,030,571)	(1,327,427)
Operating expenses
Selling and marketing	159,156	286,784	338,497	430,008
Research and development		67,033		75,033
General and administrative	5,236,018	663,415	9,121,614	1,225,115
Total operating expenses	5,395,174	1,017,232	9,460,111	1,730,156
Loss from operations	(6,177,834)	(1,385,796)	(10,490,682)	(3,057,583)
Other income (expense)
Interest income (expense), net	(90,010)	11,501	(93,800)	25,153
Financing Costs	(1,774,750)		(2,299,632)
Change in fair value of derivative liabilities	814,213		3,053,071
Amortization of debt discount	(4,229,977)		(6,049,639)
Other income (expense)	63,450	26,511	52,095	26,511
Total other income (expense)	(5,217,074)	38,012	(5,337,905)	51,664
Loss before provision for income taxes	(11,394,908)	(1,347,784)	(15,828,587)	(3,005,919)
Provision for income taxes	0	0	0	0
Net loss	$ (11,394,908)	$ (1,347,784)	$ (15,828,587)	$ (3,005,919)
Loss per share attributable to common stockholders
Basic (in Dollars per share)	$ (0.32)	$ (0.04)	$ (0.47)	$ (0.10)
Diluted (in Dollars per share)	$ (0.32)	$ (0.04)	$ (0.47)	$ (0.10)
Weighted average shares outstanding
Basic (in Shares)	36,100,385	30,531,365	33,435,964	30,523,860
Diluted (in Shares)	36,100,385	30,531,365	33,435,964	30,523,860
Other Comprehensive loss
Net loss	$ (11,394,908)	$ (1,347,784)	$ (15,828,587)	$ (3,005,919)
Unrealized gain from marketable securities	57,476		40
Comprehensive loss	$ (11,337,432)	$ (1,347,784)	$ (15,828,547)	$ (3,005,919)

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated) (Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]
Balances at Dec. 31, 2014	$ (8,047,574)	$ 3,000	$ 30,497	$ (1,209,600)	$ 15,315,110	$ (22,078,193)	$ (108,388)
Balances (in Shares) at Dec. 31, 2014		3,000,000	30,496,909	(60,000)
Stock-based compensation	4,292,209				4,292,209
Exercise of warrants	278,951		$ 206		278,745
Exercise of warrants (in shares)			206,480
Issuance of shares to settle accounts payable	$ 364,728		$ 1,633		363,095
Issuance of shares to settle accounts payable (in shares)	1,633,047		1,633,047
Conversions of convertible notes payable	$ 5,810,512		$ 11,938		5,798,574
Conversions of convertible notes payable (in shares)			11,937,099
Issuance of warrants in connection with convertible notes payable	3,861,962				3,861,962
Unrealized gain from marketable securities	40						40
Net loss	(15,828,587)					(15,828,587)
Balances at Jun. 30, 2015	$ (9,267,759)	$ 3,000	$ 44,274	$ (1,209,600)	$ 29,909,695	$ (37,906,780)	$ (108,348)
Balances (in Shares) at Jun. 30, 2015		3,000,000	44,273,535	(60,000)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (15,828,587)	$ (3,005,919)
Adjustments to reconcile net loss to net cash:
Depreciation and amortization	64,691	38,953
Provisions and allowances		60,000
Gain on sale of investments and property and equipment		(9,600)
Charges from escrow deposits	240,400
Inventory valuation reserve	354,939
Market value of securities received for services		(98,532)
Unrealized gain on marketable securities held for resale		(26,511)
Change in fair value of derivative liability	(3,053,071)
Amortization of debt discount	6,049,639
Financing costs	2,299,632
Stock based compensation	4,292,209
Changes in operating assets and liabilities
Accounts receivable	8,774	(29,362)
Inventories	228,634	(37,791)
Deposits in escrow	20,076
Prepaid insurance	(338,875)
Prepaid expenses and other assets	(185,916)	(213,261)
Accounts payables	1,659,988	193,384
Accrued interest payable	165,657
Accrued expenses	(488,135)
Accrued settlement and severance expenses	1,004,486
Customer deposits	(311,000)	863,137
Deferred revenue	(51,304)	458,051
Deferred costs	(299,018)
Net cash provided by (used in) operating activities	(4,166,781)	(1,807,451)
Cash flows from investing activities
Issuance of note receivable		(40,000)
Purchase of intangible assets, net		(195,002)
Net cash used in investing activities		(235,002)
Cash flows from financing activities
Payments on notes payable	(12,434)	1,738
Related party notes payable, net	(150,000)	404,880
Proceeds from issuance of notes payable	0	0
Proceeds from issuance of common stock, net		2,442,859
Proceeds from issuance of convertible notes payable, net	4,642,300
Proceeds from issuance of convertible notes payable from related parties, net	150,000
Net cash provided by financing activities	4,629,866	2,849,477
Net decrease in cash	463,085	807,024
Cash, beginning of period	101,182	168,003
Cash, end of period	564,267	975,027
Supplemental disclosures of cash flow information:
Cash paid for interest	1,151	2,872
Cash paid for income tax	0	0
Non- cash investing and financing activities:
Marketable securities received for accounts receivable		$ 196,000
Common stock issued upon debt conversion	5,810,512
Common stock issued for accounts payable	365,000
Stock Issued For Accounts Payable [Member]
Non- cash investing and financing activities:
Common stock issued for accounts payable	$ 364,728

Business Organization, Nature o

Business Organization, Nature of Operations	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Business Organization, Nature of Operations	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS Medbox, Inc, which is incorporated in the state of Nevada (the “Company”), provides specialized consulting services to the marijuana industry and sells associated patented products, including its Medbox medical dispensing system and medical vaporization devices. The Company works with clients who seek to enter the medical and cultivation marijuana markets in those states where approved. Medbox offers turnkey solutions that assist with licensing and compliance, site selection, design and permitting, safety and security, along with full build-out and operational oversight. The Company’s consulting solutions and technology create structure and process for clients and their respective businesses in this rapidly emerging sector. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (“VII”), the Company sells a line of vaporizer and accessory products online and through distribution partners. The Company is headquartered in Los Angeles, California. The Company holds the license to operate a dispensary in Portland, Oregon, and a master lease on the property in which the dispensary is located. The Company entered into an Operating Agreement with an unrelated party (the “Operator”) in which the Operator will manage and operate the Dispensary. Per the terms of the Agreement, the Dispensary is “under the exclusive supervision and control of Operator, which shall be responsible for the proper and efficient operation of the Dispensary”. The term of the Agreement includes an initial term, which is five years, and a renewal term for an additional five years. The renewal term is at the discretion of the Operator. The procurement fee for the dispensary was $400,000 (initially classified in Deferred Revenue), of which $50,000 was paid upon execution and delivery of the Agreement, and the remaining $350,000 is to be paid monthly in the amount of gross receipts less payroll and costs of inventories. If the procurement fees are not paid within six months, the payment terms become a minimum monthly payment of $5,000. The remaining $350,000 is evidenced by a Note Receivable to the Company. As of June 30, 2015 the Company is not assured of the timing of the collectability of the Note Receivable and therefore has set up an allowance in the amount of $350,000 for the Note Receivable, and has reduced the Deferred Revenue to $50,000. After the Procurement Fee is paid in full, it is the parties’ plan that ownership of the Dispensary (through a new merged corporation) will be apportioned 51% to Operator and 49% to Medbox. The Agreement also includes an annual Licensor Fee of 5% of the annual Gross Revenues, which will begin after the Procurement Fees have been paid in full. The Company has determined that they do not hold the controlling financial interest in the Dispensary and are not the primary beneficiary, and therefore will not consolidate the Dispensary in their financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries: • Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below. • Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories. • Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. • MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington. • Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS). • Medicine Dispensing Systems, Inc., an Arizona corporation, which distributes our Medbox dispensing system and provides related consulting services in the State of Arizona. All intercompany transactions, amounts and balances have been eliminated. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets, the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates. Basis of Presentation The accompanying unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. The results for the three and six months ended June 30, 2015 are not necessarily indicative of results to be expected for a full year, any other interim periods or any future year or period. The accompanying unaudited interim financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 26, 2015. The condensed consolidated balance sheet data as of December 31, 2014 was derived from audited consolidated financial statements. The Company has performed a review of all subsequent events through the date the unaudited interim financial statements were issued, and has determined that no additional disclosures are necessary. Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in California, Oregon, and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2015 and December 31, 2014, the Company’s uninsured balances totaled $96,422 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of approximately $0 and $286,000 for the three months ended June 30, 2015 and 2014, respectively and approximately $0 and $430,000 for the six months ended June 30, 2015 and 2014, respectively. Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 5). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) June 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 2,047,673 — — 2,047,673 Total $ 2,142,490 $ 21,650 $ — $ 2,120,840 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the six months ended June 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 3,186,431 Reclassified to equity upon conversion (1,777,540 ) Change in fair value of conversion feature (3,053,071 ) Ending balance $ 2,047,673 Revenue Recognition We enter into transactions with clients who require our expertise and are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights) to obtain the necessary licenses to operate a dispensary for the location, and to consult in daily operations of the dispensary. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out. Medbox machines retail for approximately $50,000 for each machine set (including the POS system), and normally our contracts include the sale of the dispensary units within the scope of options to be provided that might also include location build out costs. Currently, our standard contracts have a five year term, call for an upfront, non-refundable consulting fee, and contain options including acquiring a Medbox dispensary machine and having the Company perform the buildouts for the location, at set prices. The Company has determined these optional purchases each constitute a separate purchasing decision, and therefore are considered a separate arrangement for revenue recognition purposes. Revenue on each of these options are evaluated for recognition when and if the customer decides to enter into the arrangement. Based on these contracts, and other auxiliary agreements, our current revenue model consists of the following income streams: Consulting fee revenues and buildouts Consulting fee revenues is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. The majority of the consulting fees arise from the upfront, non-refundable consulting fee in our standard contract, and is recognized over the life of the contract. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue for the buildouts of the dispensary, if the customer chooses to have it performed by the Company, is recognized after issuance of a certificate of occupancy for the newly completed facility. Other revenue includes sales of territory, location, and management rights The Company at times enters into specific contracts to assign exclusive location and management rights, for a dispensary, that the Company has been granted through a license approved by local authorities. These rights are transferred under a management rights agreement to an operator for retail, dispensary, or cultivation centers. The Company also has one agreement with a related party in which they granted the related party the exclusive rights to a certain territory. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. In the sale of the territory rights to the related party, the revenue is being recognized over the term of the agreement. Revenues on VII product sales. Revenue from referral fees. Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs. Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that opened in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. Basic and Fully Diluted Net Income/Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the three and six months ending June 30, 2015 and 2014, due to the net loss, as they would have an anti-dilutive effect on EPS. As of June 30, 2015 and 2014, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. Additionally the Company has approximately 8,650,000 warrants to purchase common stock outstanding as of June 30, 2015. The Company also has approximately $4,806,000 in convertible debentures outstanding at June 30, 2015, whose underlying shares were not included that are convertible at the holders’ option at a conversion price of the lower of $0.88 or 51% of the VWAP over the last 40 days prior to conversion (subject to reset upon a future dilutive financing). Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC No. 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. An IRS audit is still open on the year ended December 31 2011, in which the Company received a notice of deficiency for the amount of approximately $60,000. The Company does not concur with the IRS findings and is in the process of challenging the determination Commitments and Contingencies Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Going Concern The accompanying unaudited interim financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of approximately $37,907,000 as of June 30, 2015. During the six months ended June 30, 2015, the Company had a net loss of approximately $15,829,000, negative cash flow from operations of approximately $4,167,000 and negative working capital of approximately $11,513,000. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is in negotiations with lenders to secure additional financing in the third quarter of 2015. Management is also planning to conduct a road show after the last half of 2015. The Company expects that these plans will provide it the necessary liquidity to continue operations for the next 12 months. To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time. Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventories	NOTE 3 – INVENTORIES Inventories are stated at the lower of cost or market value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. The consolidated inventories at June 30, 2015 and December 31, 2014 consist of the following: June 30, 2015 December 31, 2014 Work in process and related capitalized costs $ — $ 308,867 Deposits on dispensing machines, net of valuation reserve of $293,473 at June 30, 2015 32,500 325,973 Vaporizers and accessories 235,163 154,930 Dispensing machines 110,000 171,466 Total inventory, net $ 377,663 $ 961,236 On May 4, 2015, AVT, Inc., the manufacturing partner of the Company announced that they had commenced a voluntary filing for restructuring and court protection under Chapter 11 of the United States Bankruptcy Code. Dispensing machines and Deposits on dispensing machines noted in schedule above are with AVT. Additionally, during the second quarter of 2015, the Company completed a strategic review of the Medbox machines and concluded that they would take a reduced role in future marketing efforts. As a result of the strategic review, the Company evaluated the inventory and the related deposits in connection with reduced demand and concluded a write down of both assets was required. The bankruptcy of the manufacturing partner further complicates the process to convert the inventory and advances to cash and therefore is an additional factor in the decision to write down the inventory and record a valuation reserve against the deposits. Accordingly, the Company has evaluated the realizability of the dispensing machines and deposits, and has written the inventory down by $61,466 to an estimated net realizable value of $110,000 and recorded a valuation reserve against the deposits of $293,473 resulting in net deposits of $32,500, during the three months ended June 30, 2015. Work in process and related capitalized costs includes costs to build out a dispensary in Portland, Oregon that opened in the second quarter of 2015 (Note 1). The costs related to the Portland dispensary have been classified in deferred costs until the related revenue is recognized.

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	NOTE 4 – MARKETABLE SECURITIES On May 19, 2014 the Company entered into a six month agreement with a publicly traded company that provides real estate financing and related solutions to licensed marijuana operators, under which the other entity issued approximately 200,000 warrants to the Company as consideration for referral fees. The Company exercised 33,333 warrants into 10,825 shares of common stock of the other entity, through the cashless exercise option, leaving the Company with 166,665 warrants. The warrants’ fair value of $73,167 as of June 30, 2015 was determined using the Black Scholes Merton model with the following assumptions: estimated term of one year, annual risk-free rate of .26%, and annualized expected volatility of 120%. The fair value of the shares as of June 30, 2015 was $ 21,650. The Company uses the published closing price of the stock to value the stock held by the Company.

Convertible Notes Payable and D

Convertible Notes Payable and Derivative Liability	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Convertible Notes Payable and Derivative Liability	NOTE 5 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY On July 21, 2014, as amended on September 19, 2014 and October 20, 2014, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“July 2014 Debentures”) in the aggregate principal amount of $3,500,000, in five tranches. The initial closing in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. The second closing in the amount of $1,000,000 occurred on August 26, 2014; the third of $500,000 on September 26, 2014. The fourth and fifth, each in the amount of $500,000, were to occur within 2 and 5 business days, respectively, of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the July 2014 Debentures. The Registration statement was withdrawn and terminated in December 2014, and a new registration statement was filed on April 9, 2015. The July 2014 Debentures bear interest at the rate of 10% per year. The debt is due July 21, 2015, with the original agreement calling for amortization payments, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following eight successive months thereafter. Also on September 19, 2014, as amended on October 20, 2014, the Company entered into a securities purchase agreement pursuant to which it agreed to issue convertible debentures (“September 2014 Debentures”) in the aggregate principal amount of $2,500,000, in two tranches. The initial closing in the principal amount of $1,000,000 occurred on September 19, 2014. The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Debentures. The September 2014 Debentures bear interest at the rate of 5% per year. The debt is due September 19, 2015, and the original agreement called for amortization payments, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance. Both the original July 2014 Purchase Agreement Debentures and September 2014 Debentures prior to subsequent amendment, share the following significant terms: All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price. The Notes were initially convertible into shares of the Company’s common stock at the initial Fixed Conversion Price of $11.75 per share. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share is lower than the Fixed Conversion Price, then the conversion price will be reduced to equal such price. The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. Through subsequent modifications of the July 2014 Debentures and September 2014 Debentures, the required date to file the registration statement and the effective date of the registration statement have been changed to April 15, 2015 and July 15, 2015, respectively. The registration statement was filed on April 9, 2015, and became effective on June 11, 2015. The conversion feature of the July 2014 Debenture and the September 2014 debenture meets the definition of a derivative and due to the reset provision to occur upon subsequent sales of securities at a price lower than the fixed conversion price, requires bifurcation and is accounted for as a derivative liability. The derivative was initially recognized at its estimated fair value of approximately $1,885,000 and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative is measured and recognized at fair value each subsequent reporting period and the changes in fair value are recognized in the Statement of Operations as Change in fair value of derivative liability. For the six months ended June 30, 2015 the Company recognized a loss on the change in fair value of derivative liabilities of approximately $3,053,000 (including the change in fair value related to the new convertible debentures issued in the first and second quarters of 2015 discussed below). See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative. On January 30, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the Purchase Agreement (the “Purchase Agreement Amendment” or the “Modification”) pursuant to which the Investors agreed to purchase an additional $1,800,000 in seven Modified Closings: (1) $200,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 to be funded within thirty (30) days of the Closing; (3) $100,000 to be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (4) $100,000 to be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; (5) $500,000 to be funded within two days of the date that the Registration Statement is declared effective by the SEC; (6) $500,000 to be funded within five days of the date that the Registration Statement is declared effective by the SEC; and (7) $100,000 to be funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment. The Modification also eliminated the amortization payments discussed above, and provided for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates. The Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015(which was later modified to April 30, 2015). The Company must also file the Registration Statement by March 8, 2015 (later amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture. As noted above, the Registration Statement was filed on April 9, 2015, and became effective June 11, 2015. On March 13, 2015 the Company and the Investors entered into a further amendment (“March 2015 Amendment”) to the July 21, 2014, 10% Convertible debentures, as amended January 30, 2015, whereby the reset of the fixed conversion rate to $1.83 caused by recent dilutive issuances was reiterated for all previously issued notes. In addition, the March 2015 Amendment modified the opening date of the Portland, Oregon dispensary to be April 30, 2015. Neither of these modified terms had an impact on the accounting treatment of the Debentures. The July 2014 financing was further modified on March 23, 2015. The closing dates of the financing were again modified, investments by two members of the Board of Director’s (“Board”) was required, and the deadline for filing of the registration statement was changed to no later than April 15, 2015, and its effective date to no later than July 15, 2015. Neither of these modified terms had an impact on the accounting treatment of the Debentures. On April 9, 2015, the Company and their investors entered into an Amendment, Modification and Supplement to the July 2014 convertible debenture, which amends the closings as set forth in the March 23, 2015 Modification, to increase the amounts due in the third tranche, due two days after the filing of the Registration Statement, to $450,000. On January 28, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the September 2014 Debenture, pursuant to which the remaining $1,500,000 will be funded in four Modified Closings as set forth in the agreement, and contains other modifications with the same terms as was contained in the January 30, 2015 Modification. The Company considered if the above modifications should be accounted for as an extinguishment or modification of the existing debt. The Company first evaluated if the modification of terms could be considered a troubled debt restructuring, but the modification did not meet the criteria as the Investors did not grant a concession to the Company for economic or legal reasons related to any financial difficulties of the Company. The majority of the modifications related to deadlines being extended for certain required events. The only financial modification was to revise the payment schedule on the Debentures to eliminate the amortization payments and instead require all to be due at maturity. The Company concluded this is not regarded as a concession as it is not the forgiveness of any interest payments, nor reduction of principal, nor change to the maturity date. Therefore, the modification of the terms was evaluated to determine if the changes in the Debentures’ future cash flows were in excess of 10% and considered substantial, which would require the Debentures to be accounted for as extinguished and replaced with new debt. As the modification resulted in a less than 10% estimated change in future cash flows, the Company concluded that the modification of the terms of the July 2014 and September 2014 Debentures was to be accounted for as a modification of the existing Debentures. As part of the January 30, 2015 Modification, the Parties entered into a Modified Debenture Agreement for the $200,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The fixed conversion price of the Modified Debenture was the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the older fixed conversion price. As a result of the reset to the conversion price, at January 30, 2015, the derivative liability was remeasured to a fair value of approximately $2,690,000, using a weighted probability model as estimated by management. A decrease in fair value of the derivative liability of approximately $1,072,000 was recognized as a gain on the Statement of Consolidated Comprehensive Loss in the six months ended June 30, 2015. The additional Modified Debentures under the July 2014 Debentures closed on February 27, 2015 in the amount of $100,000, March 13, 2015 in the amount of $50,000, March 16, 2015 in the amount of $25,000, March 20, 2015 in the amount of $75,000 and on March 26, 2015 in the amount of $150,000. All these Modified Debentures have a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $5 fixed conversion price. This reset resulted in the derivative liability being revalued at February 27, 2015, using a weighted probability model for a fair value of $2,720,000, for a decrease in fair value of approximately $334,000, recognized as a gain on the Statement of Consolidated Comprehensive Loss. The additional Modified Debentures under the September 2014 Debentures closed on January 29, 2015 in the amount of $100,000 and February 24, 2015 in the amount of $100,000. These Modified Debentures have a fixed conversion price of the lower of $5.00 or 51% of the VWAP for the last 20 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $5.00 fixed conversion price. The resulting reset and remeasurement of the fair value of the derivative liability is included in the amounts of the change to fair value discussed above. The additional fundings of the July 2014 Modified Debentures under the closing schedule detailed above resulted in $2,811,500 being received during the second quarter. The first $300,000 had a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 40 days prior to the conversion. The April 17, 2015 closing contained a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $1.83 fixed conversion price. This reset resulted in the derivative liability being revalued at April 17, 2015, using a weighted probability model for a fair value of $3,287,000, for a increase in fair value of approximately $1,764,000, recognized as a loss on the Statement of Consolidated Comprehensive Loss. There was additional funding of $1,300,000 of the September 2014 Modified Debentures under the closing schedule detailed above. These Modified Debentures all have a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion. The Directors convertible debentures required under the March 23, 2015 Modification, issued in the first quarter of 2015, total $150,000, and have a three year term and an interest rate of 8% per annum. They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion. As with the Modified Debentures, the debentures included a reset provision, which resulted in the conversion feature being bifurcated and accounted for as a derivative liability, with an initial fair value of $132,175. The director’s convertible debentures also reset on February 27, 2015 and April 17, 2015, with the changes to fair value included in the amounts disclosed above. The Modified Debentures also included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, with a three year term. The warrants issued in the six months ended June 30, 2015 in connection with all the Modified Debentures are summarized below: Date issued Number of warrants Exercise price Fair Value July 2014 Modified Debentures January 30, 2015 40,552 $ 4.93 $ 159,601 February 26, 2015 45,537 2.20 79,904 March 13, 2015 21,151 2.36 39,965 March 16, 2015 10,575 2.36 19,981 March 20, 2015 41,946 1.79 59,942 March 27, 2015 75,758 1.98 119,888 April 2, 2015 60,386 1.66 74,025 April 2, 2015 30,193 1.66 37,012 April 10,2015 107,194 1.39 112,460 April 17,2015 41,667 1.20 37,680 April 24,2015 127,119 1.18 112,635 April 24, 2015 21,186 1.18 18,772 May 1, 2015 156,250 .96 113,133 May 7, 2015 134,615 .78 79,234 May 8, 2015 42,000 .75 23,768 May 15, 2015 200,000 .75 113,365 May 22, 2015 250,000 .60 113,366 May 29, 2015 258,621 .58 112,537 June 5, 2015 288,462 .52 120,738 June 12, 2015 930,233 .43 303,246 June 19, 2015 3,448,276 .29 751,159 September 2014 Modified Debentures January 28, 2015 18,038 5.54 80,156 February 13, 2015 57,870 1.73 96,689 April 2, 2015 181,159 1.66 222,109 April 24, 2015 90,579 1.10 80,548 May 15, 2015 200,000 .75 113,365 June 12, 2015 1,744,186 .43 570,248 Directors January 5, 2015 6,173 8.10 39,901 January 30, 2015 10,142 4.93 39,916 February 2, 2015 10,204 4.90 16,619 Total 8,650,792 3,861,962 The Company determined that the warrants were properly classified in equity as there is no cash settlement provision and the warrants have a fixed exercise price and therefore result in an obligation to deliver a known number of shares. As a result of the conversion feature being bifurcated and recognized as a derivative liability, the Company evaluated the warrants and determined that they have a sufficient number of authorized and unissued shares as of June 30, 2015, after consideration of the subsequent increased authorized shares, (See Note 10), to settle all existing commitments. The Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the earliest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of earliest inception date first until either all of the convertible debentures are converted or settled. During the six months ended June 30, 2015, $2,900,000 principal of the July 2014 Debentures and $1,100,000 principal and approximately $27,000 accrued interest of the September 2014 Debentures were converted into 12,383,229 of the Company’s common shares at an average price of $0.74, based on 51% of the calculated VWAP. As a result of the conversions approximately $90,000 of the related debt discount was immediately amortized as Amortization of debt discount on the Statement of Comprehensive Loss. Upon conversion, the derivative fair value for the amounts converted were remeasured through the date of conversion, with the resulting decrease of fair value of approximately $1,160,000 recognized on the Statement of Consolidated Comprehensive Loss. At the same time, the fair value of the conversion feature derivative liability related to the amount converted was reclassified to equity.

Restricted Stock and Restricted

Restricted Stock and Restricted Stock Units ("RSUs")	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Restricted Stock and Restricted Stock Units ("RSUs")	NOTE 6 – RESTRICTED STOCK AND RESTRICTED STOCK UNITS (“RSUs”) On July 23, 2014, in connection with the election of a new Chairman, President and CEO, the Company entered into a two year employment contract with the new CEO. Under the employment contract, the CEO received an award of RSU’s, to be issued within 90 days of the effective date of the Employment Agreement, under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant. The Company also agreed to make an equal stock award to the CEO on each anniversary date of the employment agreement. The fair value of the awards, as determined on grant date, was $711,500 which is being amortized over the CEO’s one year service period. On August 21, 2014, the Compensation Committee of the Board granted Restricted Stock and RSU’s to two Board members who were elected to the Board on April 9, 2014. Under the award, the Directors received 346,875 shares of restricted stock and 121,875 RSU’s under which the holders have the right to receive 121,875 shares of common stock. The grant date fair value of the restricted stock was $3,607,500 and the grant date fair value of the RSU’s was $1,267,500. The restricted Stock and RSU’s vested over the remaining first year of the new Board members’ term ending on March 31, 2015. The fair value of the grant was amortized over the period from the date of grant, August 21, 2014 to the end of the first year of the Board members’ term, March 31, 2015. Under the Board members’ contracts, additional grants will be made for the second year of the contract. During October 2014, the Compensation Committee of the Board granted 19,452 RSU’s to a new Board member who was elected to the Board on October 22, 2014. The Board member’s contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015, which vest quarterly. On February 10, 2015, the Compensation Committee of the Board granted 100,174 RSU’s to certain officers and employees of the Company as for retention and bonuses. The grant date fair value of the RSU’s was approximately $114,000. The RSU’s vest every six months through December 31, 2016. The fair value of the grant is being amortized over the period from the date of grant, February 10, 2015 through the vesting dates in six month increments. On January 15, 2015, the Board granted 75,000 RSUs to a consultant, which vest in 25,000 installments quarterly through July 15, 2015, beginning with 25,000 which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $450,000. On May 11, 2015, the Board granted 38,600 RSUs to various officers and employees, which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $20,000, which was immediately expensed. In connection with the former CEO’s separation agreement (Note 9) approximately 2,580,000 options with a 10 year term were granted at an exercise price of $0.13. The fair value of $335,117 was calculated using the Black Sholes Merton model, and was immediately expensed. On May 11, 2015, the new CEO (Note 9) was awarded 196,078 RSUs in connection with his retention agreement. The grant date fair value of the RSU’s was approximately $100,000. The RSUs vest quarterly through May 11, 2016. A summary of the activity related to restricted stock and RSUs for the six months ended June 30, 2015 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2015 168,750 $ 10.40 Restricted stock granted — — Restricted stock vested (168,750 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at June 30, 2015 — $ — Restricted stock units (RSU’s) Total shares Grant date fair RSU’s non-vested at January 1, 2015 199,584 $ 10.70 RSU’s granted 412,354 $ 0.51 - $6.07 RSU’s vested (189,016 ) $ 0.51 - $6.07 RSU’s forfeited — RSU’s non-vested June 30, 2015 422,922 $ 0.51 - $11.00 A summary of the expense related to restricted stock, RSUs and stock option awards for the three and six months ended June 30, 2015 is presented below: Summary of the expense related to Restricted Stock and RSUs For the three For the six Restricted Stock 390,000 1,845,942 RSU’s 1,055,550 2,111,150 Stock options 335,117 335,117 Total $ 1,780,667 $ 4,292,209

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 – RELATED PARTY TRANSACTIONS The aggregate amount of outstanding payables to related parties as of June 30, 2015 and December 31, 2014 was $474,888 and $678,877, respectively. During the year ended December 31, 2014, the Company issued four notes payable to PVM International Inc. (“PVMI”), a related party which is 100% owned by a co-founder of the Company, in the amounts of $250,000, $100,000, $500,000, and $375,000. These notes were subsequently partially repaid leaving $284,488 outstanding as of June 30, 2014. On October 17, 2014 the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. On March 28, 2014, the Company entered into an agreement with a related party for territory rights in Colorado for $500,000. The agreement has a term of five years and in accordance with the Company’s revenue policy, the revenue will be recognized over the five year term. Approximately $375,000 remains in deferred revenue as of June 30, 2015. During the third quarter of 2014, the Company created the following affiliated entities in connection with license applications: A. Hanna Growers, Inc., Herbal Choice of Illinois, Inc., Nature’s Treatment of Illinois, Inc., Green Blossom of Illinois, Inc., Midwestern Compassionate Care of Illinois, Inc., Midwestern Wellness Group of Illinois, Inc., Green Blossom, Inc., Nature’s Treatment, Inc. and Herbal Choice, Inc.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholder's Equity	NOTE 8 – STOCKHOLDER’S EQUITY Common Stock For common shares which were issued upon conversion of the convertible debentures during the six months ended June 30, 2015 see Note 5. During the six months ended June 30, 2015 the Company issued 1,633,047 shares of its common stock, valued at approximately $365,000 as based on the market price of the common stock on the date of settlement, as a payment of certain accounts payables. In addition, the Company issued 206,480 of their common stock upon exercise of the warrants held by various previous owners of VII.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company leases property for its day to day operations and has recently begun leasing facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses. Office Leases On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a monthly rate of $14,397. Starting July 1, 2014, the monthly rent increased by 3% to $14,828 per month. The Company moved to new offices in Los Angeles, CA in April 2015. The sublease on the new office has a term of 18 months and with monthly rent of $7,486. The Company plans to sublease the office in West Hollywood, CA. Total rent expense under operating leases for the three months ended June 30, 2015 and 2014 was $66,000 and $58,000, respectively. Rent expense for the six months ended June 30, 2015 and 2014 was approximately $110,000 and $114,000, respectively. Retail/Cultivation facility leases The Company’s business model of acquiring retail dispensary and cultivation licenses has made it important to acquire real estate either through lease arrangements or through purchase agreements in order to secure a possible license. On May 8, 2014, the Company entered into a lease agreement for the Portland dispensary for five years with a monthly payment of $7,400 in order to apply for a license and build-out of a location for a client. Also, on July 22, 2014 one of the Company’s subsidiaries Medbox Property Investments, Inc., entered into a new lease for a facility which will be used in the application process for both a dispensary and cultivation facility. The Company paid an initial security deposit of $30,000 and the lease is payable monthly at a rate of $20,000 per month. The lease has a five year term, but is contingent upon license approval which allows for early termination of the lease after January 1, 2015 if the license is not granted. Due to the fact that the Company was unsuccessful in obtaining the license related to the mentioned facility the lease agreement was terminated in November 2014 and the Company forfeited the security deposit. The following table is a summary of our material contractual lease commitments as of June 30, 2015: Year Ending Office Rent Retail/Cultivation Facility Lease 2015 $ 133,884 $ 44,400 2016 245,310 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 468,162 $ 340,400 Real Estate Commitments As part of the changes in the Company’s business model, the Company entered into various real estate purchase agreements at various times in order to allow the filing of retail dispensary or cultivation facility licenses in certain states and localities. These purchase agreements generally provide for a period of due diligence and a termination clause in the event that the Company is unable to obtain a license for its client. The agreements generally also provide for some monthly payment from escrow in order to compensate the real estate owner for the passage of time until the sale transaction is complete. Most of these payment releases from escrow are nonrefundable but applicable towards the purchase price if the Company decides to proceed with the purchase. Subject to approval of the license for a dispensary or cultivation center, the Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased. Through December 31, 2014 the Company paid $930,000 either by deposit into twelve escrow accounts or direct payments to sellers, to secure the purchase and/or extend the closing dates on real estate to be used for future retail/cultivation facilities with an aggregate purchase price of $26,830,000. The real estate purchase agreements have closing dates varying between December 1, 2014 and February 10, 2015. No additional deposits were made during the six months ended June 30, 2015 and one additional escrow was closed. During the year 2014, the Company allowed the escrows to expire on three agreements with an aggregate purchase price of $3,195,000 and forfeited $140,000 in earnest money due to unfavorable terms demanded by the sellers to extend the escrow and closing date. The Company was not successful in obtaining licenses for another ten locations with an aggregated sales price of $21,515,000 and deposits in escrow totaling $685,000. As a result all escrow accounts were closed with $235,757 forfeited and $419,167 refunded to the Company in 2014, and $30,076 refunded during the first quarter of 2015. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000. A summary of open real estate purchase transactions as of June 30, 2015 is represented in the table below: Property Purchase price Closing date Net escrow balance Date escrow opened Additional rents/ to extend closing date 1 $ 360,000 07/19/2015 55,000 06/28/2014 $ 22,308 2 — 25,000 07/21/2014 — Total $ 360,000 $ 80,000 $ 22,308 During 2014, the Company entered into numerous real estate contracts in the state of San Diego to secure locations during the licensing process. The contracts allow the Company to demonstrate to licensing authorities that the locations are available for use as a dispensary or cultivation location. During the second quarter the Company terminated additional licensing efforts on seven properties and accordingly wrote off $240,400 of escrow deposits. Line 2 represents the balance of advance from San Diego escrow deposits assigned to the Company by PVMI used to secure properties for licensing process in San Diego, the assignment agreement is described in the “Related parties transaction” footnote. Officers On June 30, 2015, Guy Marsala, President, Chief Executive Officer, and director of the Company since July 23, 2014, tendered his resignation as President and Chief Executive Officer of the Company and as a director on the Company’s board, effective immediately. Mr. Marsala confirmed that such resignation is not because of a disagreement with the Company on any matter relating to its operations, policies or practices. In connection with his resignation, the Company and Mr. Marsala entered into a Separation Agreement dated June 30, 2015. Pursuant to the terms of the Separation Agreement, Mr. Marsala is entitled to receive $500,000 in severance pay, payable in equal monthly installments of $30,000, and a grant of options to purchase up to $335,275 of shares of common stock at an exercise price based on the closing price of the Company’s common stock on June 30, 2015, in lieu of any rights under his employment agreement, which was terminated. Chief Operating Officer/Chief Executive Officer On April 22, 2015, the Board of Company appointed Jeffrey Goh as Chief Operating Officer, effective immediately. In connection with his appointment as Chief Operating Officer, Mr. Goh and the Company have agreed that Mr. Goh’s annual base salary will be $300,000, subject to annual increases of between 5% and 7% based upon performance goals and the Company’s financial results. Mr. Goh will be eligible to receive a cash bonus of up to a maximum of $150,000 per year (“Cash Bonus”), plus a bonus grant of restricted stock units convertible into Company common stock up to a maximum of $150,000 per year (“Equity Bonus”). Each of the Cash Bonus and Equity Bonus shall be determined based upon the achievement of performance goals to be mutually agreed upon amongst Mr. Goh and the Board of Directors for the given year. Mr. Goh shall also be entitled to receive an award of 100,000 restricted stock units convertible into Company common stock on each anniversary of the original date of his employment with the Company. In the event that Mr. Goh terminates his employment with or without cause or the Company terminates Mr. Goh’s employment without cause, Mr. Goh shall be entitled to receive a severance payment equivalent to 6, 12, or 18 months of base salary, based upon whether the length of Mr. Goh’s employment with the Company at the time of termination is less than 12 months, greater than 12 months but less than 24 months, or greater than 24 months, respectively. Effective June 30, 2015, Jeffrey Goh, was promoted to President and interim Chief Executive Officer of the Company. New Lease The Company entered into a new lease for new offices in Los Angeles, CA on April 7, 2015, which terminates on September 29, 2016. The sublease on the new office has a term of 18 months and with monthly rent of approximately $7,500. The Company plans to sublease the office in West Hollywood, CA. Litigation On May 22, 2013, Medbox initiated litigation in the United States District Court in the District of Arizona against three shareholders of MedVend Holdings LLC (“Medvend”) in connection with a contemplated transaction that Medbox entered into for the purchase of an approximate 50% ownership stake in Medvend for $4.1 million. The lawsuit alleges fraud and related claims arising out of the contemplated transaction during the quarter ended June 30, 2013. The litigation is pending and Medbox has sought cancellation due to a fraudulent sale of the stock because the selling shareholders lacked the power or authority to sell their ownership stake in MedVend, and their actions were a breach of representations made by them in the agreement. On November 19, 2013 the litigation was transferred to United States District Court for the Eastern District of Michigan. MedVend recently joined the suit pursuant to a consolidation order executed by a new judge assigned to the matter. In the litigation, the selling shareholder defendants seek alternatively to have the transaction performed, or to have it unwound and be awarded damages and allege breach of the agreement by Medbox and that $600,000 was wrongfully retained by the Company. Medbox has denied liability with respect to any and all such counterclaims. A new litigation schedule was recently issued setting trial for September 2015. On June 5, 2014, the Company entered into a purchase and sale agreement (the “Medvend PSA”) with PVM International, Inc. (“PVMI”) concerning this matter. Pursuant to the Medvend PSA, the Company sold to PVMI the Company’s rights and claims attributable to or controlled by the Company against those three certain stockholders of Medvend, known as Kaplan, Tartaglia and Kovan (the “Medvend Rights and Claims”), in exchange for the return by PVMI to the Company of 30,000 shares of the Company’s common stock. PVMI is owned by Vincent Mehdizadeh, the Company’s largest stockholder. The Company will have the right, under the Medvend PSA, to purchase from PVMI, at any time, the Medvend Rights and Claims, for the consideration provided by PVMI, plus the sum of any of PVMI’s reasonable expenditures incurred in pursuit of the Medvend Rights and Claims. The court has not yet ruled on the substitution of PVMI as plaintiff in this matter. If necessary, the Company plans to vigorously defend against this matter. The case is in the discovery stage, and, at this time, the Company cannot determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can they reasonably estimate a range of potential loss, should the outcome be unfavorable. On February 20, 2015 Michael A. Glinter, derivatively and on behalf of nominal defendants Medbox, Inc. the Board and certain executive officers (Pejman Medizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanskai, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer Love, and C. Douglas Mitchell) filed a suit in the Superior Court of the State of California for the County of Los Angeles. The suit alleges breach of fiduciary duties and abuse of control by the defendants. Relief is sought awarding damages resulting from breach of fiduciary duty and to direct the Company and the defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. This action has been stayed pending the outcome of the actions filed in the United States District Court for the District of Nevada (Calabrese and Gray). Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 21, 2015 Josh Crystal on behalf of himself and of all others similarly situated filed a class action lawsuit in the U.S. District Court for Central District of California against Medbox, Inc., and certain past and present members of the Board (Pejman Medizadeh, Bruce Bedrick, Thomas Iwanskai, Guy Marsala, and Douglas Mitchell). The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief of compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before September 25, 2015. The Company intends to vigorously defend against these suits. Due to the early stages of the suits the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 18, 2015, Ervin Gutierrez filed a class action lawsuit in the U.S. District Court for the Central District of California. The suit alleges violations of federal securities laws through public announcements and filings that were materially false and misleading when made because they misrepresented and failed to disclose that the Company was recognizing revenue in a manner that violated US GAAP. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before September 25, 2015. The Company intends to vigorously defend against this suit. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 29, 2015, Matthew Donnino filed a class action lawsuit in the U.S. District Court for Central District of California. The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before September 25, 2015. The Company intends to vigorously defend against this suit. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On February 12, 2015, Jennifer Scheffer, derivatively on behalf of nominal defendant Medbox , filed a lawsuit in the Eighth Judicial District Court of Nevada seeking damages for breaches of fiduciary duty regarding the issuance and dissemination of false and misleading statements and regarding allegedly improper and unfair related party transactions, unjust enrichment and waste of corporate assets. On April 17, 2015, Ned Siegel and Mitchell Lowe filed a Motion to Dismiss. On April 20, 2015, the Company filed a Joinder in the Motion to Dismiss. On July 27, 2015, the Court held a hearing on the Motion to Dismiss, and upon the conclusion of oral argument, the Court took the matter under submission. On August 10, 2015, the Court issued its Decision granting the Motion to Dismiss without prejudice. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On March 10, 2015 Robert J. Calabrese, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against certain Company officers and/or directors (Ned L. Siegel, Guy Marsala, J. Mitchell Lowe, Pejman Vincent Mehdizadeh, Bruce Bedrick, and Jennifer S. Love). The suit alleges breach of fiduciary duties and gross mismanagement by issuing materially false and misleading statements regarding the Company’s financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods. Specifically the suit alleges that defendants caused the Company to overstate the Company’s revenues by recognizing revenue on customer contracts before it had been earned. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On March 27, 2015 Tyler Gray, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanski, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, and C. Douglas Mitchell). The suit alleges breach of fiduciary duties and abuse of control. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On May 20, 2015 Patricia des Groseilliers, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Ned Siegel, Guy Marsala, J. Mitchell Lowe, Bruce Bedrick, Jennifer S. Love, Matthew Feinstein, C. Douglas Mitchell, and Thomas Iwanski). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On June 3, 2015 Mike Jones, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the U.S. District Court for Central District of California against the Company’s Board of Directors and certain executive officers (Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, C. Douglas Mitchell, Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, and Thomas Iwanski). The suit alleges breach of fiduciary duties, abuse of control, and breach of duty of honest services. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. On July 20, 2015, the Court issued an Order consolidating this litigation with those previously consolidated in the Central District (Crystal, Gutierrez, and Donnino). Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On July 20, 2015 Kimberly Freeman, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the Eighth Judicial District Court of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Guy Marsala, Ned Siegel, J. Mitchell Lowe, Jennifer S. Love, C. Douglas Mitchell, and Bruce Bedrick). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On December 26, 2014, Medicine Dispensing Systems, a wholly-owned subsidiary of Medbox, filed a suit against Kind Meds, Inc. to collect fees of approximately $550,000 arising under a contract to establish a dispensary. Kind Meds, Inc. filed a cross complaint against Medicine Dispensing Systems for breach of contract and breach of implied covenant of good faith and fair dealing, claiming damages of not less than $500,000. We believe that the cross complaint is without merit. We will continue to pursue Kind Meds for the amounts owed under the contract and will vigorously defend ourselves against the cross complaint. At this time the Company in unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. The Company commenced arbitration proceedings against a former employee on June 13, 2013 related to employment claims asserted by the employee. Thereafter, the employee filed a suit in Los Angeles County Superior Court. The suit was stayed pending the outcome of the arbitration and thereafter dismissed without prejudice. The Company obtained a favorable arbitration award. The Company then filed an Application to Confirm the Arbitration Award in Arizona Superior Court, Maricopa County. After being unable to serve the employee, the Company performed service by publication and filed proofs of publication for service on the employee on February 27, 2015 and March 2, 2015. If the arbitration award is not enforced, the employee’s claim can be re-filed in California. In October 2014, the Board of Directors of the Company appointed a special board committee (the “Special Committee”) to investigate a federal grand jury subpoena pertaining to the Company’s financial reporting which was served upon the Company’s accountants as well as certain alleged wrongdoing raised by a former employee of the Company. The Company was subsequently served with two SEC subpoenas in early November 2014. The Company is fully cooperating with the grand jury and the SEC. In connection with its investigation of these matters, the Special Committee in conjunction with the Audit Committee initiated an internal review by management and by an outside professional advisor of certain prior period financial reporting of the Company. The outside professional advisor reviewed the Company’s revenue recognition methodology for certain contracts for the third and fourth quarters of 2013. As a result of certain errors discovered in connection with the review by management and its professional advisor, the Audit Committee, upon management’s recommendation, concluded on December 24, 2014 that the consolidated financial statements for the year ended December 31, 2013 and for the third and fourth quarters therein, as well as for the quarters ended June 30, 2014, June 30, 2014 and September 30, 2014, should no longer be relied upon and would be restated to correct the errors. On March 6, 2015 the audit committee determined that the consolidated financial statements for the year ended December 31, 2012, together with all three, six and nine month financial information contained therein, and the quarterly information for the first two quarters of the 2013 fiscal year should also be restated. On March 11, 2015, the Company filed its restated Form 10 Registration Statement with the SEC with restated financial information for the years ended December 31, 2012 and December 31, 2013, and on March 16, 2015, the Company filed amended and restated quarterly reports on Form 10-Q, with restated financial information for the periods ended June 30, June 30 and September 30, 2014, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS Share purchase and transfer On March 5, 2015, Mr. Mehdizadeh announced that an agreement has been executed with Lizada Capital LLC, an investor in the field of legal cannabis products, that would result in the transfer of the majority of Mr. Mehdizadeh’s shares of the Company to that firm. As of June 30, 2015, the prospective buyer has cancelled this agreement. Authorized share increase On June 30, 2015, the Board of Directors of the Company and the holders of a majority of the Company’s voting securities approved by written consent an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of the Company’s common stock from 100,000,000 shares to 400,000,000 shares, par value of $0.001 per share. The Company’s Board of Directors approved the increase of authorized capital so that it will have sufficient shares of common stock available for issuance upon the conversion or exercise of currently outstanding convertible debt securities and warrants and for future capital raises. The Company intends to file with the Securities and Exchange Commission a Schedule 14C Information Statement regarding the matter submitted to a vote of their security holders. The increase of authorized capital approved by the stockholders will not become effective until at least 20 days following the date on which a definitive Schedule 14C Information Statement is mailed to their stockholders of record as of June 30, 2015. Acquisition agreement On July 24, 2015, the Company entered into an Agreement of Purchase and Sale of Membership Interest (the “Acquisition Agreement”) with East West Secured Development, LLC (the “Seller”) to purchase 100% of the membership interest of EWSD I, LLC (“EWSD”) which has entered into an agreement with Southwest Farms, Inc. (“Southwest”) to purchase certain real property comprised of 320-acres of agricultural land in Pueblo, Colorado (the “Acquired Property”). The purchase price to acquire EWSD consists of (i) $500,000 paid by the Company as a deposit into the escrow for the Acquired Property in the form of a note to the Seller that shall be terminated upon the Closing, and (ii) the Company’s payment to Seller of a royalty of 3% of the adjusted gross revenue, if any, from operation of the Acquired Property (including sale of any portion of or interest in the Acquired Property less any applicable expenses) for the three-year period beginning on January 1, 2016 payable 50% in cash and 50% in Company common stock (the “Royalty Payment”). The number of shares due in connection with any such payment shall be determined by dividing the dollar amount of such payment by the volume-weighted average price of the Company’s common shares for the thirty trading days prior to the due date of the payment. Adjusted gross revenue means gross revenue after deduction of Colorado state cannabis sales tax. In connection with EWSD’s purchase of the Acquired Property, EWSD entered into a secured promissory note (the “Note”) with Southwest in the principal amount of $3,670,000. Interest on the outstanding principal balance of the Note shall accrue at the rate of five percent (5.0%) per annum. The Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon an amortization period of thirty years, commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018. The Note is secured by a deed of trust (the “Deed of Trust”), security agreement, assignment of rents (“Assignment of Rents and Leases”) and financing statement encumbering the Acquired Property. In connection with the Closing, EWSD will also enter into an unsecured promissory note (the “Unsecured Note”) with the Seller, in respect of earnest money payments previously made by Seller to Southwest, in the principal amount of $830,000. Interest on the outstanding principal balance of the Unsecured Note shall accrue at the rate of six percent (6.0%) per annum. The Unsecured Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon a hypothetical amortization period of thirty years, commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018. On August 7, 2015 the Company closed escrow, completing the agreement to purchase 100% of the membership interest of EWSD which entered into an agreement with Southwest to purchase certain real property comprised of 320-acres of agricultural land in Pueblo, Colorado for approximately $5 million as described above. The Company has determined that the Acquired Property is an acquisition of assets and does not constitute a business. Prior to its acquisition by the Company, the Acquired Property was leased to a farmer who cultivated corn on 150 of its 320 acres. The Company intends to engage an independent contractor to manage the operations and hire its own new staff to cultivate hemp and marijuana on the Acquired Property. No employees of the former farm will work in the new operation. The new operation will have an entirely new customer base, sales force and marketing plan as well as new production techniques and a new trade name. Securities purchase agreement On August 14, 2015, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“August 2015 Debentures”) in the aggregate principal amount of up $3,979,877 to fund in up to 11 tranches. The initial closing in the aggregate principal amount of $650,000 occurred on August 14, 2015. The second closing in the amount of $185,000 will occur on August 28, 2015, the third closing in the amount of $125,000 will occur on September 4, 2015, the fourth through seventh closings will be in the amount of $60,000 each and will occur beginning on September 11, 2015 with the remaining 3 closings occurring every 2 weeks thereafter, the eighth closing in the amount of $250,000 will occur 3 days after the filing of a registration statement, the ninth closing in the amount of $250,000 will occur 8 days after the filing of a registration statement, the tenth closing in the amount of $1,278,877 will occur within 3 business days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the August 2015 Debentures and the eleventh closing, at the sole option of the purchaser in the amount of up to $1,000,000 will occur by October 15, 2015. The August 2015 Debentures bear interest at the rate of 10% per year. The debt related to the first tranche is due August 14, 2016. The August 2015 Debentures contain the following significant terms: All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price. The conversion price is the lower of (a) $0.75, or (b) a 49% discount to the lowest daily VWAP (as reported by Bloomberg) of the Common Stock during the 30 trading days prior to the conversion date. The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 51% of the lowest volume weighted average price of the common stock for the 30 prior trading days. In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries: • Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below. • Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories. • Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. • MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington. • Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS). • Medicine Dispensing Systems, Inc., an Arizona corporation, which distributes our Medbox dispensing system and provides related consulting services in the State of Arizona. All intercompany transactions, amounts and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets, the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. The results for the three and six months ended June 30, 2015 are not necessarily indicative of results to be expected for a full year, any other interim periods or any future year or period. The accompanying unaudited interim financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 26, 2015. The condensed consolidated balance sheet data as of December 31, 2014 was derived from audited consolidated financial statements. The Company has performed a review of all subsequent events through the date the unaudited interim financial statements were issued, and has determined that no additional disclosures are necessary.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in California, Oregon, and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2015 and December 31, 2014, the Company’s uninsured balances totaled $96,422 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of approximately $0 and $286,000 for the three months ended June 30, 2015 and 2014, respectively and approximately $0 and $430,000 for the six months ended June 30, 2015 and 2014, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Embedded derivative - The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 5). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) June 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 2,047,673 — — 2,047,673 Total $ 2,142,490 $ 21,650 $ — $ 2,120,840 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the six months ended June 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 3,186,431 Reclassified to equity upon conversion (1,777,540 ) Change in fair value of conversion feature (3,053,071 ) Ending balance $ 2,047,673
Revenue Recognition	Revenue Recognition We enter into transactions with clients who require our expertise and are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights) to obtain the necessary licenses to operate a dispensary for the location, and to consult in daily operations of the dispensary. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out. Medbox machines retail for approximately $50,000 for each machine set (including the POS system), and normally our contracts include the sale of the dispensary units within the scope of options to be provided that might also include location build out costs. Currently, our standard contracts have a five year term, call for an upfront, non-refundable consulting fee, and contain options including acquiring a Medbox dispensary machine and having the Company perform the buildouts for the location, at set prices. The Company has determined these optional purchases each constitute a separate purchasing decision, and therefore are considered a separate arrangement for revenue recognition purposes. Revenue on each of these options are evaluated for recognition when and if the customer decides to enter into the arrangement. Based on these contracts, and other auxiliary agreements, our current revenue model consists of the following income streams: Consulting fee revenues and buildouts Consulting fee revenues is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. The majority of the consulting fees arise from the upfront, non-refundable consulting fee in our standard contract, and is recognized over the life of the contract. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue for the buildouts of the dispensary, if the customer chooses to have it performed by the Company, is recognized after issuance of a certificate of occupancy for the newly completed facility. Other revenue includes sales of territory, location, and management rights The Company at times enters into specific contracts to assign exclusive location and management rights, for a dispensary, that the Company has been granted through a license approved by local authorities. These rights are transferred under a management rights agreement to an operator for retail, dispensary, or cultivation centers. The Company also has one agreement with a related party in which they granted the related party the exclusive rights to a certain territory. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. In the sale of the territory rights to the related party, the revenue is being recognized over the term of the agreement. Revenues on VII product sales. Revenue from referral fees.
Cost of Revenue	Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs.
Inventory	Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that opened in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator.
Basic and Fully Diluted Net Income/Loss Per Share	Basic and Fully Diluted Net Income/Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the three and six months ending June 30, 2015 and 2014, due to the net loss, as they would have an anti-dilutive effect on EPS. As of June 30, 2015 and 2014, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. Additionally the Company has approximately 8,650,000 warrants to purchase common stock outstanding as of June 30, 2015. The Company also has approximately $4,806,000 in convertible debentures outstanding at June 30, 2015, whose underlying shares were not included that are convertible at the holders’ option at a conversion price of the lower of $0.88 or 51% of the VWAP over the last 40 days prior to conversion (subject to reset upon a future dilutive financing).
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC No. 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. An IRS audit is still open on the year ended December 31 2011, in which the Company received a notice of deficiency for the amount of approximately $60,000. The Company does not concur with the IRS findings and is in the process of challenging the determination
Commitments and Contingencies	Commitments and Contingencies Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Going Concern	Going Concern The accompanying unaudited interim financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of approximately $37,907,000 as of June 30, 2015. During the six months ended June 30, 2015, the Company had a net loss of approximately $15,829,000, negative cash flow from operations of approximately $4,167,000 and negative working capital of approximately $11,513,000. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is in negotiations with lenders to secure additional financing in the third quarter of 2015. Management is also planning to conduct a road show after the last half of 2015. The Company expects that these plans will provide it the necessary liquidity to continue operations for the next 12 months. To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) June 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 2,047,673 — — 2,047,673 Total $ 2,142,490 $ 21,650 $ — $ 2,120,840
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the six months ended June 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 3,186,431 Reclassified to equity upon conversion (1,777,540 ) Change in fair value of conversion feature (3,053,071 ) Ending balance $ 2,047,673

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The consolidated inventories at June 30, 2015 and December 31, 2014 consist of the following: June 30, 2015 December 31, 2014 Work in process and related capitalized costs $ — $ 308,867 Deposits on dispensing machines, net of valuation reserve of $293,473 at June 30, 2015 32,500 325,973 Vaporizers and accessories 235,163 154,930 Dispensing machines 110,000 171,466 Total inventory, net $ 377,663 $ 961,236

Convertible Notes Payable and20

Convertible Notes Payable and Derivative Liability (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Summary of Warrants Issued in Connection with Modified Debentures	The warrants issued in the six months ended June 30, 2015 in connection with all the Modified Debentures are summarized below: Date issued Number of warrants Exercise price Fair Value July 2014 Modified Debentures January 30, 2015 40,552 $ 4.93 $ 159,601 February 26, 2015 45,537 2.20 79,904 March 13, 2015 21,151 2.36 39,965 March 16, 2015 10,575 2.36 19,981 March 20, 2015 41,946 1.79 59,942 March 27, 2015 75,758 1.98 119,888 April 2, 2015 60,386 1.66 74,025 April 2, 2015 30,193 1.66 37,012 April 10,2015 107,194 1.39 112,460 April 17,2015 41,667 1.20 37,680 April 24,2015 127,119 1.18 112,635 April 24, 2015 21,186 1.18 18,772 May 1, 2015 156,250 .96 113,133 May 7, 2015 134,615 .78 79,234 May 8, 2015 42,000 .75 23,768 May 15, 2015 200,000 .75 113,365 May 22, 2015 250,000 .60 113,366 May 29, 2015 258,621 .58 112,537 June 5, 2015 288,462 .52 120,738 June 12, 2015 930,233 .43 303,246 June 19, 2015 3,448,276 .29 751,159 September 2014 Modified Debentures January 28, 2015 18,038 5.54 80,156 February 13, 2015 57,870 1.73 96,689 April 2, 2015 181,159 1.66 222,109 April 24, 2015 90,579 1.10 80,548 May 15, 2015 200,000 .75 113,365 June 12, 2015 1,744,186 .43 570,248 Directors January 5, 2015 6,173 8.10 39,901 January 30, 2015 10,142 4.93 39,916 February 2, 2015 10,204 4.90 16,619 Total 8,650,792 3,861,962

Restricted Stock and Restrict21

Restricted Stock and Restricted Stock Units ("RSUs") (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the activity related to restricted stock and RSUs for the six months ended June 30, 2015 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2015 168,750 $ 10.40 Restricted stock granted — — Restricted stock vested (168,750 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at June 30, 2015 — $ — Restricted stock units (RSU’s) Total shares Grant date fair RSU’s non-vested at January 1, 2015 199,584 $ 10.70 RSU’s granted 412,354 $ 0.51 - $6.07 RSU’s vested (189,016 ) $ 0.51 - $6.07 RSU’s forfeited — RSU’s non-vested June 30, 2015 422,922 $ 0.51 - $11.00
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	A summary of the expense related to restricted stock, RSUs and stock option awards for the three and six months ended June 30, 2015 is presented below: Summary of the expense related to Restricted Stock and RSUs For the three For the six Restricted Stock 390,000 1,845,942 RSU’s 1,055,550 2,111,150 Stock options 335,117 335,117 Total $ 1,780,667 $ 4,292,209

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Summary of Material Contractual Lease Commitments	The following table is a summary of our material contractual lease commitments as of June 30, 2015: Year Ending Office Rent Retail/Cultivation Facility Lease 2015 $ 133,884 $ 44,400 2016 245,310 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 468,162 $ 340,400
Summary of Open Real Estate Purchase Transactions	A summary of open real estate purchase transactions as of June 30, 2015 is represented in the table below: Property Purchase price Closing date Net escrow balance Date escrow opened Additional rents/ to extend closing date 1 $ 360,000 07/19/2015 55,000 06/28/2014 $ 22,308 2 — 25,000 07/21/2014 — Total $ 360,000 $ 80,000 $ 22,308

Business Organization, Nature23

Business Organization, Nature of Operations - Additional Information (Detail) - Jun. 30, 2015 - USD ($)	Total
Business Organization, Nature Of Operations [Line Items]
Note receivable, allowance	$ 350,000
Operating Agreement [Member]
Business Organization, Nature Of Operations [Line Items]
Agreement term	5 years
Agreement renewal term	5 years
Procurement fee for the dispensary	$ 400,000
Procurement fee paid upon execution and delivery of agreement	50,000
Procurement fee due amount	350,000
Minimum monthly payment	5,000
Deferred revenue	50,000
Note receivable, allowance	$ 350,000
Procurement fee payment terms	If the procurement fees are not paid within six months, the payment terms become a minimum monthly payment of $5,000.
Ownership percentage, by parent	51.00%
Ownership percentage	49.00%
Annual licensor fee	5.00%

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Additional Information (Detail)	Jan. 30, 2015$ / shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)d$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Mar. 13, 2015$ / shares	Jan. 28, 2015USD ($)	Dec. 31, 2014USD ($)shares	Sep. 30, 2014$ / shares	Sep. 19, 2014USD ($)	Jul. 21, 2014USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash, FDIC Insured Amount		$ 250,000		$ 250,000
Cash, Uninsured Amount		96,422		$ 96,422				$ 0
Cash, Uninsured Amount Description				The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
Advertising Expense		0	$ 286,000	$ 0	$ 430,000
Revenues		$ 84,365	360,105	$ 150,757	351,115
Preferred Stock, Shares Outstanding (in Shares) | shares		3,000,000		3,000,000				3,000,000
Warrants to purchase common stock outstanding | shares		8,650,792		8,650,792
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 0.88		$ 0.88					$ 11.75
Conversion, percentage of weighted average price				51.00%
Period of volume weighted average price calculation | d				40
Accumulated deficit		$ (37,906,780)		$ (37,906,780)				$ (22,078,193)
Net loss		(11,394,908)	$ (1,347,784)	(15,828,587)	(3,005,919)
Net cash used in operating activities				(4,166,781)	$ (1,807,451)
Working capital		(11,513,000)		(11,513,000)
Internal Revenue Service (IRS) [Member]
Summary Of Significant Accounting Policies [Line Items]
Tax deficiency amount				$ 60,000
Open tax year				2,011
Dispensing machines [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenues				$ 50,000
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Principal amount of Debt		$ 4,806,000		$ 4,806,000			$ 1,500,000			$ 2,500,000	$ 3,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 5	$ 1.83		$ 1.83		$ 1.83
Conversion, percentage of weighted average price	51.00%			51.00%
Series A Preferred Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred Stock, Shares Outstanding (in Shares) | shares		3,000,000	3,000,000	3,000,000	3,000,000
Preferred Stock, No Par Value (in Dollars per share) | $ / shares		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | shares		15,000,000	15,000,000	15,000,000	15,000,000

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 94,817	$ 94,776
Derivative Liability	2,047,673	$ 3,691,853
Total	2,142,490
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	21,650
Derivative Liability	0
Total	21,650
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0
Derivative Liability	0
Total	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	73,167
Derivative Liability	2,047,673
Total	$ 2,120,840

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Detail)	6 Months Ended
	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Beginning balance	$ 3,691,853
Additions	3,186,431
Reclassified to equity upon conversion	(1,777,540)
Change in fair value of conversion feature	(3,053,071)
Ending balance	$ 2,047,673

Inventories - Schedule of Inven

Inventories - Schedule of Inventory, Current (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Work in process and related capitalized costs		$ 308,867
Inventory	$ 377,663	961,236
Deposits on dispensing machines [Member]
Inventory [Line Items]
Inventory	32,500	325,973
Vaporizers and Accessories [Member]
Inventory [Line Items]
Inventory	235,163	154,930
Dispensing machines [Member]
Inventory [Line Items]
Inventory	$ 110,000	$ 171,466

Inventories - Schedule of Inv28

Inventories - Schedule of Inventory, Current (Parenthetical) (Detail)	Jun. 30, 2015USD ($)
Inventory [Line Items]
Inventory, valuation reserve	$ 293,473
Deposits on dispensing machines [Member]
Inventory [Line Items]
Inventory, valuation reserve	$ 293,473

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory written down	$ 61,466
Inventory	377,663	$ 961,236
Inventory, valuation reserve	293,473
Deposits on dispensing machines [Member]
Inventory [Line Items]
Inventory	32,500	325,973
Inventory, valuation reserve	293,473
Dispensing machines [Member]
Inventory [Line Items]
Inventory	$ 110,000	$ 171,466

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	May. 19, 2014	Jun. 30, 2015
Schedule of Trading Securities and Other Trading Assets [Line Items]
Class of warrant or rights, outstanding		8,650,792
Fair value of warrants		$ 3,861,962
Other Entity [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Class of warrant or right, issued	200,000
Investment, Term of Investment	6 months
Class of warrant or right, exercised	33,333
Shares of common stock issued on exercise of warrants	10,825
Class of warrant or rights, outstanding	166,665
Fair value of warrants		$ 73,167
Expected term		1 year
Annual risk-free rate		0.26%
Annualized expected volatility		120.00%
Class of Warrant or Rights, Fair Value Granted		$ 21,650

Convertible Notes Payable and31

Convertible Notes Payable and Derivative Liability - Additional Information (Detail) - USD ($)

Apr. 17, 2015

Apr. 14, 2015

Apr. 11, 2015

Apr. 09, 2015

Feb. 27, 2015

Jan. 30, 2015

Sep. 26, 2014

Sep. 19, 2014

Aug. 26, 2014

Jul. 21, 2014

Jun. 30, 2015

Jun. 30, 2015

Mar. 26, 2015

Mar. 20, 2015

Mar. 16, 2015

Mar. 13, 2015

Feb. 24, 2015

Jan. 29, 2015

Jan. 28, 2015

Sep. 30, 2014

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 4,642,300

Debt Instrument, Convertible, Conversion Price

$ 0.88

$ 0.88

$ 11.75

Debt instrument, convertible, terms of conversion feature

The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Change in fair value of derivative liabilities

$ 3,053,000

Minimum percentage of change in present value of future cash flows

10.00%

Maximum estimated percentage of resulted change in present value of future cash flows

10.00%

Conversion, percentage of weighted average price

51.00%

Consecutive trading days

20 days

Decrease in fair value of derivative liabilities

$ 814,213

$ 3,053,071

Weighted probability model for the fair value

$ 3,287,000

$ 2,720,000

Derivative gain recognized

334,000

1,160,000

Derivative loss recognized

$ 1,764,000

Cash settlement provision for warrants classified in equity

0

$ 0

Debt converted to common shares

12,383,229

Amortization of debt discount

$ 4,229,977

$ 6,049,639

Common Stock [Member]

Debt Conversion [Line Items]

Debt Instrument, Convertible, Conversion Price

$ 0.74

$ 0.74

Conversion of Convertible Debentures [Member]

Debt Conversion [Line Items]

Amortization of debt discount

$ 90,000

Debt Instrument, Tranche Three [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 450,000

Debt Instrument, Due after filing

2 days

July 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 2,900,000

2,900,000

Debt redemption amount

$ 100,000

$ 150,000

$ 75,000

$ 25,000

$ 50,000

September 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 1,100,000

$ 1,100,000

Debt Instrument, Convertible, Conversion Price

$ 5

$ 5

Debt instrument, convertible, terms of conversion feature

Modified Debentures have a fixed conversion price of the lower of $5.00 or 51% of the VWAP for the last 20 days prior to the conversion.

Conversion, percentage of weighted average price

51.00%

Consecutive trading days

20 days

Debt redemption amount

$ 100,000

$ 100,000

Accrued interest of debt

$ 27,000

July 2014 and September 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Convertible, Conversion Price

$ 5

$ 5

Convertible Debt [Member]

Debt Conversion [Line Items]

Debt instrument, maturity date

Sep. 19, 2015

Jul. 21, 2015

Debt Instrument, Face Amount

$ 2,500,000

$ 3,500,000

$ 4,806,000

$ 4,806,000

$ 1,500,000

Proceeds from convertible debt

$ 1,000,000

$ 150,000

Convertible notes, interest rate

5.00%

10.00%

Debt Instrument, Description

In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. Through subsequent modifications of the July 2014 Debentures and September 2014 Debentures, the required date to file the registration statement and the effective date of the registration statement have been changed to April 15, 2015 and July 15, 2015, respectively. The registration statement was filed on April 9, 2015, and became effective on June 11, 2015.

Debt Instrument, Convertible, Conversion Price

$ 5

$ 1.83

$ 1.83

$ 1.83

Debt instrument, convertible, terms of conversion feature

They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion.

Derivative liability fair value

$ 2,690,000

$ 1,885,000

$ 132,175

$ 132,175

Conversion, percentage of weighted average price

51.00%

51.00%

Consecutive trading days

20 days

20 days

Decrease in fair value of derivative liabilities

$ 1,072,000

Convertible debt instrument term

3 years

Debt instrument effective percentage

8.00%

8.00%

Warrant instrument grant agreement, description

The Modified Debentures also included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, with a three year term.

Convertible Debt [Member] | Agreed Funding at the Closing of the Purchase Agreement Amendment [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 1,800,000

Convertible Debt [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

200,000

Convertible Debt [Member] | Funded within thirty (30) days of the closing [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

100,000

Convertible Debt [Member] | Funded within two days following the filing of a registration statement with the SEC to register the shares underlying the debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

100,000

Convertible Debt [Member] | Funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

100,000

Convertible Debt [Member] | Funded within two days of the date that the Registration Statement is declared effective by the SEC [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

500,000

Convertible Debt [Member] | Funded within five days of the date that the Registration Statement is declared effective by the SEC [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

500,000

Convertible Debt [Member] | Funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 100,000

Convertible Debt [Member] | Debt Instrument, Tranche One [Member]

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 1,000,000

Convertible Debt [Member] | Debt Instrument, Tranche Two [Member]

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 1,000,000

Convertible Debt [Member] | Debt Instrument, Tranche Three [Member]

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 500,000

Convertible Debt [Member] | Debt Instrument, Tranche Four [Member]

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 500,000

Convertible Debt [Member] | Debt Instrument Tranche Five [Member]

Debt Conversion [Line Items]

Proceeds from convertible debt

$ 500,000

Convertible Debt [Member] | July 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 300,000

$ 300,000

Proceeds from convertible debt

$ 2,811,500

Debt Instrument, Payment Terms

The original agreement calling for amortization payments, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following eight successive months thereafter.

Debt Instrument, Convertible, Conversion Price

$ 0.88

$ 1.83

$ 1.83

Debt instrument, convertible, terms of conversion feature

The first $300,000 had a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 40 days prior to the conversion. The April 17, 2015 closing contained a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion.

Conversion, percentage of weighted average price

51.00%

51.00%

Consecutive trading days

40 days

40 days

Convertible Debt [Member] | September 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Face Amount

$ 1,300,000

$ 1,300,000

Debt Instrument, Payment Terms

The original agreement called for amortization payments, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.

Debt Instrument, Description

The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Debentures.

Debt Instrument, Convertible, Conversion Price

$ 0.88

$ 0.88

Debt instrument, convertible, terms of conversion feature

Modified Debentures all have a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion.

Conversion, percentage of weighted average price

51.00%

Consecutive trading days

40 days

Convertible Debt [Member] | July 2014 and September 2014 Convertible Debentures [Member]

Debt Conversion [Line Items]

Debt Instrument, Convertible, Conversion Price

$ 1.83

$ 1.83

Convertible Notes Payable and32

Convertible Notes Payable and Derivative Liability - Summary of Warrants Issued in Connection with Modified Debentures (Detail) - Jun. 30, 2015 - USD ($)	Total
Class of Warrant or Right [Line Items]
Number of warrants	8,650,792
Fair Value	$ 3,861,962
Directors [Member] | January 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	10,142
Exercise price	$ 4.93
Fair Value	$ 39,916
Directors [Member] | January 5, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	6,173
Exercise price	$ 8.10
Fair Value	$ 39,901
Directors [Member] | February 2, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	10,204
Exercise price	$ 4.90
Fair Value	$ 16,619
July 2014 Modified Debentures [Member] | January 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	40,552
Exercise price	$ 4.93
Fair Value	$ 159,601
July 2014 Modified Debentures [Member] | February 26, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	45,537
Exercise price	$ 2.20
Fair Value	$ 79,904
July 2014 Modified Debentures [Member] | March 13, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	21,151
Exercise price	$ 2.36
Fair Value	$ 39,965
July 2014 Modified Debentures [Member] | March 16, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	10,575
Exercise price	$ 2.36
Fair Value	$ 19,981
July 2014 Modified Debentures [Member] | March 20, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	41,946
Exercise price	$ 1.79
Fair Value	$ 59,942
July 2014 Modified Debentures [Member] | March 27, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	75,758
Exercise price	$ 1.98
Fair Value	$ 119,888
July 2014 Modified Debentures [Member] | April 2, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	60,386
Exercise price	$ 1.66
Fair Value	$ 74,025
July 2014 Modified Debentures [Member] | April 2, 2015 Second Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	30,193
Exercise price	$ 1.66
Fair Value	$ 37,012
July 2014 Modified Debentures [Member] | April 10, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	107,194
Exercise price	$ 1.39
Fair Value	$ 112,460
July 2014 Modified Debentures [Member] | April 17, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	41,667
Exercise price	$ 1.20
Fair Value	$ 37,680
July 2014 Modified Debentures [Member] | April 24, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	127,119
Exercise price	$ 1.18
Fair Value	$ 112,635
July 2014 Modified Debentures [Member] | April 24, 2015 Second Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	21,186
Exercise price	$ 1.18
Fair Value	$ 18,772
July 2014 Modified Debentures [Member] | May 1, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	156,250
Exercise price	$ 0.96
Fair Value	$ 113,133
July 2014 Modified Debentures [Member] | May 7, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	134,615
Exercise price	$ 0.78
Fair Value	$ 79,234
July 2014 Modified Debentures [Member] | May 8, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	42,000
Exercise price	$ 0.75
Fair Value	$ 23,768
July 2014 Modified Debentures [Member] | May 15, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	200,000
Exercise price	$ 0.75
Fair Value	$ 113,365
July 2014 Modified Debentures [Member] | May 22, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	250,000
Exercise price	$ 0.60
Fair Value	$ 113,366
July 2014 Modified Debentures [Member] | May 29, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	258,621
Exercise price	$ 0.58
Fair Value	$ 112,537
July 2014 Modified Debentures [Member] | June 5, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	288,462
Exercise price	$ 0.52
Fair Value	$ 120,738
July 2014 Modified Debentures [Member] | June 12, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	930,233
Exercise price	$ 0.43
Fair Value	$ 303,246
July 2014 Modified Debentures [Member] | June 19, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	3,448,276
Exercise price	$ 0.29
Fair Value	$ 751,159
September 2014 Modified Debentures [Member] | January 28, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	18,038
Exercise price	$ 5.54
Fair Value	$ 80,156
September 2014 Modified Debentures [Member] | February 13, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	57,870
Exercise price	$ 1.73
Fair Value	$ 96,689
September 2014 Modified Debentures [Member] | April 2, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	181,159
Exercise price	$ 1.66
Fair Value	$ 222,109
September 2014 Modified Debentures [Member] | April 24, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants	90,579
Exercise price	$ 1.10
Fair Value	$ 80,548
September 2014 Modified Debentures [Member] | May 15, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	200,000
Exercise price	$ 0.75
Fair Value	$ 113,365
September 2014 Modified Debentures [Member] | June 12, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants	1,744,186
Exercise price	$ 0.43
Fair Value	$ 570,248

Restricted Stock and Restrict33

Restricted Stock and Restricted Stock Units ("RSUs") - Additional Information (Detail)	May. 11, 2015USD ($)shares	Apr. 01, 2015shares	Feb. 10, 2015USD ($)shares	Jan. 15, 2015USD ($)shares	Aug. 21, 2014USD ($)Personshares	Jul. 23, 2014USD ($)	Oct. 31, 2014shares	Jun. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employment Agreement, Term						2 years
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award								Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant
Stock Issued During Period, Value, Restricted Stock Award, Gross | $						$ 711,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period						1 year
Number of Board Members | Person					2
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $					$ 3,607,500
Number of shares granted					346,875			0
Number of shares vested on grant date								168,750
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $					$ 1,267,500
Number of shares granted					121,875			412,354
Number of shares underlying restricted stock					121,875
Number of shares vested on grant date								189,016
Restricted Stock Units (RSUs) [Member] | Board Of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted		100,000					19,452
Restricted Stock Units (RSUs) [Member] | Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $	$ 20,000		$ 114,000
Number of shares granted	38,600		100,174
Vesting period description								The RSU's vest every six months through December 31, 2016.
Number of shares vested on grant date	38,600
Restricted Stock Units (RSUs) [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $				$ 450,000
Number of shares granted				75,000
Vesting period description								Vest in 25,000 installments quarterly through July 15, 2015, beginning with 25,000 which vested immediately on the grant date.
Number of shares vested on grant date				25,000
Restricted Stock Units (RSUs) [Member] | Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted								2,580,000
Shares granted in period, term								10 years
Shares granted in period, exercise price | $ / shares								$ 0.13
Fair value of shares granted | $								$ 335,117
Restricted Stock Units (RSUs) [Member] | New Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $	$ 100,000
Number of shares granted	196,078
Vesting period description								The RSUs vest quarterly through May 11, 2016

Restricted Stock and Restrict34

Restricted Stock and Restricted Stock Units ("RSUs") - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Detail) - $ / shares	Aug. 21, 2014	Jun. 30, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs non-vested at beginning of period		168,750
Restricted stock and RSUs granted	346,875	0
Restricted stock and RSUs vested		(168,750)
Restricted stock and RSUs forfeited		0
Restricted stock and RSUs non-vested at end of period		0
Restricted stock and RSUs non-vested at beginning of period		$ 10.40
Restricted stock and RSUs granted		0
Restricted stock and RSUs vested		10.40
Restricted stock and RSUs forfeited		0
Restricted stock and RSUs non-vested at end of period		$ 0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs non-vested at beginning of period		199,584
Restricted stock and RSUs granted	121,875	412,354
Restricted stock and RSUs vested		(189,016)
Restricted stock and RSUs forfeited		0
Restricted stock and RSUs non-vested at end of period		422,922
Restricted stock and RSUs non-vested at beginning of period		$ 10.70
Restricted stock and RSUs forfeited		0
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs granted		0.51
Restricted stock and RSUs vested		0.51
Restricted stock and RSUs non-vested at end of period		0.51
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs granted		6.07
Restricted stock and RSUs vested		6.07
Restricted stock and RSUs non-vested at end of period		$ 11

Restricted Stock and Restrict35

Restricted Stock and Restricted Stock Units ("RSUs") - Allocation of Recognized Period Costs (Detail) - Jun. 30, 2015 - USD ($)	Total	Total
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$ 1,780,667	$ 4,292,209
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	390,000	1,845,942
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	1,055,550	2,111,150
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$ 335,117	$ 335,117

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Oct. 17, 2014USD ($)Agreement	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)NotesPayable	Jun. 30, 2014USD ($)	Mar. 28, 2014USD ($)
Related Party Transactions (Details) [Line Items]
Notes Payable, Related Parties, Current		$ 474,888	$ 678,877
Escrow deposit		90,000	400,476
Deposits and other assets		172,212	$ 104,726
Territory Rights Agreement [Member]
Related Party Transactions (Details) [Line Items]
Deposits and other assets					$ 500,000
Deferred revenue		$ 375,000
Agreement term		5 years
Revenue recognition period		5 years
Affiliated Entity [Member]
Related Party Transactions (Details) [Line Items]
Escrow deposit	$ 190,400
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]
Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current				$ 284,488
Number of Promissory Notes | NotesPayable			4
Percentage of ownership by co-founder			100.00%
Number of real estate purchase agreements on which escrow deposits paid | Agreement	8
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #1 [Member]
Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount			$ 250,000
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #2 [Member]
Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount			100,000
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable 3 [Member]
Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount			500,000
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #4 [Member]
Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount			$ 375,000

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail) - 6 months ended Jun. 30, 2015 - USD ($)	Total
Stockholders Equity [Line Items]
Stock Issued During Period, shares, as a payment of certain accounts payables	1,633,047
Stock Issued During Period, value, as a payment of certain accounts payables	$ 365,000
Vaporfection International Inc. [Member]
Stockholders Equity [Line Items]
Issuance common stock upon exercise of the warrants held by various previous owners of VII	206,480

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Apr. 22, 2015USD ($)shares

Apr. 07, 2015USD ($)

Dec. 26, 2014USD ($)

Jul. 22, 2014USD ($)

Jul. 01, 2014USD ($)

Jun. 05, 2014shares

May. 08, 2014USD ($)

Aug. 01, 2011USD ($)

Apr. 30, 2015USD ($)

Jun. 30, 2015USD ($)Property

Mar. 31, 2015USD ($)

Sep. 30, 2014USD ($)

Jun. 30, 2014USD ($)

Jun. 30, 2015USD ($)Property

Jun. 30, 2014USD ($)

Dec. 31, 2014USD ($)Agreement

Nov. 19, 2013USD ($)

Jun. 30, 2013

May. 22, 2013USD ($)

Other Commitments [Line Items]

Operating Leases, Rent Expense

$ 7,500

$ 66,000

$ 58,000

$ 110,000

$ 114,000

Lease Expiration Date

Sep. 29, 2016

Sublease term

18 months

Real Estate, Purchase Price

$ 360,000

$ 360,000

Number of properties | Property

7

7

Escrow deposits wrote off

$ 240,400

Amount retained by company

$ 600,000

Mr. Marsala [Member]

Other Commitments [Line Items]

Severance payable

$ 500,000

$ 500,000

Monthly severance payments

$ 30,000

Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary

$ 300,000

Restricted stock units convertible into company common stock | shares

100,000

Severance payment term

Mr. Goh shall be entitled to receive a severance payment equivalent to 6, 12, or 18 months of base salary, based upon whether the length of Mr. Goh's employment with the Company at the time of termination is less than 12 months, greater than 12 months but less than 24 months, or greater than 24 months, respectively.

Maximum [Member] | Mr. Marsala [Member]

Other Commitments [Line Items]

Option to purchase common stock, value

$ 335,275

Maximum [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary increase, Percentage

7.00%

Cash bonus per year

$ 150,000

Annual equity bonus

$ 150,000

Minimum [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary increase, Percentage

5.00%

Employment Termination Less Than 12 Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

6 months

Employment Termination, Greater Than 12 Months But Less Than 24 Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

12 months

Employment Termination Greater Than 24 Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

18 months

Land and Building [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 20,000

$ 7,400

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

5 years

Security Deposit

$ 30,000

Real Estate, Purchase Price

$ 399,594

Notes Issued

$ 249,000

Affiliated Entity [Member] | MedVend Holdings LLC [Member]

Other Commitments [Line Items]

Ownership stake percentage

50.00%

Stock Repurchased During Period, Shares (in Shares) | shares

30,000

Investment Owned, at Cost

$ 4,100,000

Kind Meds, Inc. [Member] | Medicine Dispensing Systems [Member]

Other Commitments [Line Items]

Plaintiff past due balance

$ 550,000

Claims damages

$ 500,000

Agreement One [Member] | Land and Building [Member]

Other Commitments [Line Items]

Escrow Deposits Related to Property Sales

$ 0

$ 930,000

Payments to Acquire Real Estate

$ 26,830,000

Agreement One [Member] | Forfeiture Of Earnest Money On Potential Purchase Of Real Estate [Member] | Land and Building [Member]

Other Commitments [Line Items]

Number of Real Estate Purchase Agreements | Agreement

3

Real Estate, Purchase Price

$ 3,195,000

Earnest Money Forfeited

140,000

Office Lease, West Hollywood, California [Member]

Other Commitments [Line Items]

Operating Lease, Rent Increase, Percent

3.00%

Operating Leases, Rent Expense

$ 14,828

Lease Expiration Date

Jun. 30, 2017

Operating Leases, Rent Expense, Minimum Rentals

$ 14,397

Office Lease, Los Angeles, California [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense

$ 7,486

Sublease term

18 months

Agreement Two [Member] | Land and Building [Member]

Other Commitments [Line Items]

Escrow Deposits Related to Property Sales

685,000

Payments to Acquire Real Estate

21,515,000

Earnest Money Forfeited

235,757

Proceeds from Other Deposits

$ 30,076

$ 419,167

Commitments and Contingencies39

Commitments and Contingencies - Summary of Material Contractual Lease Commitments (Detail)	Jun. 30, 2015USD ($)
Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2,015	$ 133,884
2,016	245,310
2,017	88,968
2,018	0
2,019	0
Total	468,162
Land and Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2,015	44,400
2,016	88,800
2,017	88,800
2,018	88,800
2,019	29,600
Total	$ 340,400

Commitments and Contingencies40

Commitments and Contingencies - Summary of Open Real Estate Purchase Transactions (Detail) - Jun. 30, 2015 - USD ($)	Total
Real Estate Properties [Line Items]
Purchase price	$ 360,000
Net escrow balance	80,000
Additional rents/fees incurred to extend closing date	22,308
Property 1 [Member]
Real Estate Properties [Line Items]
Purchase price	$ 360,000
Closing date	Jul. 19, 2015
Net escrow balance	$ 55,000
Date escrow opened	Jun. 28, 2014
Additional rents/fees incurred to extend closing date	$ 22,308
Property 2 [Member]
Real Estate Properties [Line Items]
Purchase price	0
Net escrow balance	$ 25,000
Date escrow opened	Jul. 21, 2014
Additional rents/fees incurred to extend closing date	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)

Aug. 07, 2015USD ($)a

Jul. 24, 2015USD ($)aInstallments

Apr. 14, 2015USD ($)

Apr. 11, 2015USD ($)

Apr. 09, 2015USD ($)

Sep. 26, 2014USD ($)

Sep. 19, 2014USD ($)

Aug. 26, 2014USD ($)

Jul. 21, 2014USD ($)

Jun. 30, 2015USD ($)aTranches$ / sharesshares

Mar. 13, 2015$ / shares

Jan. 30, 2015$ / shares

Jan. 28, 2015USD ($)

Dec. 31, 2014USD ($)$ / sharesshares

Sep. 30, 2014$ / shares

Subsequent Event [Line Items]

Common stock, authorized | shares

100,000,000

100,000,000

Common stock, authorized after amendment | shares

400,000,000

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Escrow deposit

$ 90,000

$ 400,476

Proceeds from convertible debt

$ 4,642,300

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.88

$ 11.75

Debt instrument, convertible, terms of conversion feature

The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 2,500,000

$ 3,500,000

$ 4,806,000

$ 1,500,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

10.00%

Debt instrument, maturity date

Sep. 19, 2015

Jul. 21, 2015

Proceeds from convertible debt

$ 1,000,000

$ 150,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 1.83

$ 1.83

$ 5

Debt instrument, convertible, terms of conversion feature

They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion.

August 2015 Debentures [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt instrument, maturity date

Aug. 14, 2016

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.75

Percentage of discount to common stock valuation

49.00%

Percentage of premium

30.00%

Percentage relating to common stock valuation

51.00%

Debt instrument, convertible, terms of conversion feature

In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement.

August 2015 Debentures [Member] | Convertible Debt [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 3,979,877

August 2015 Debentures [Member] | Convertible Debt [Member] | Maximum [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Number of tranches | Tranches

11

Debt Instrument, Tranche One [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 1,000,000

Debt Instrument, Tranche One [Member] | Convertible Debt [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 650,000

Debt Instrument, Tranche Two [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 1,000,000

Debt Instrument, Tranche Two [Member] | Convertible Debt [Member] | August 28, 2015 [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

185,000

Debt Instrument, Tranche Three [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 450,000

Debt Instrument, Due after filing

2 days

Debt Instrument, Tranche Three [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 500,000

Debt Instrument, Tranche Three [Member] | Convertible Debt [Member] | September 4, 2015 [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

125,000

Debt Instrument, Tranche Four [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 500,000

Debt Instrument, Tranche Four [Member] | Convertible Debt [Member] | Beginning on September 11, 2015 [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

60,000

Debt Instrument Tranche Five [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 500,000

Debt Instrument Tranche Five [Member] | Convertible Debt [Member] | September 11, 2015 Every 2 Weeks Thereafter [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

60,000

Debt Instrument Tranche Six [Member] | Convertible Debt [Member] | September 11, 2015 Every 2 Weeks Thereafter [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

60,000

Debt Instrument Tranche Seven [Member] | Convertible Debt [Member] | September 11, 2015 Every 2 Weeks Thereafter [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 60,000

Debt Instrument, Tranche Eight [Member] | Convertible Debt [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Debt Instrument, Due after filing

3 days

Debt Instrument, Tranche Eight [Member] | Convertible Debt [Member] | 3 Days After Filing of Registration Statement [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 250,000

Debt Instrument, Tranche Nine [Member] | Convertible Debt [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Debt Instrument, Due after filing

8 days

Debt Instrument, Tranche Nine [Member] | Convertible Debt [Member] | 8 Days After Filing of Registration Statement [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 250,000

Debt Instrument, Tranche Ten [Member] | Convertible Debt [Member] | August 14, 2015 [Member]

Subsequent Event [Line Items]

Debt Instrument, Due after filing

3 days

Debt Instrument, Tranche Ten [Member] | Convertible Debt [Member] | Within 3 Business Days of Effective Date of Registration Statement [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 1,278,877

Debt Instrument, Tranche Eleven [Member] | Convertible Debt [Member] | October 15, 2015 [Member]

Subsequent Event [Line Items]

Proceeds from convertible debt

$ 1,000,000

EWSD [Member] | Secured Promissory Note [Member]

Subsequent Event [Line Items]

Royalty payment terms

Company’s payment to Seller of a royalty of 3% of the adjusted gross revenue, if any, from operation of the Acquired Property (including sale of any portion of or interest in the Acquired Property less any applicable expenses) for the three-year period beginning on January 1, 2016 payable 50% in cash and 50% in Company common stock (the “Royalty Payment”).

Debt instrument frequency description

Commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018.

Debt Instrument, Payment Terms

The Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon an amortization period of thirty years.

EWSD [Member] | Unsecured Promissory Note [Member]

Subsequent Event [Line Items]

Debt instrument frequency description

The Unsecured Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon a hypothetical amortization period of thirty years.

Debt Instrument, Payment Terms

Commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018.

EWSD [Member] | Leased property [Member]

Subsequent Event [Line Items]

Area of real estate property | a

150

Subsequent Event [Member] | EWSD [Member]

Subsequent Event [Line Items]

Business acquisition, percentage of equity interest

100.00%

100.00%

Area of real estate property | a

320

Escrow deposit

$ 500,000

Royalty percentage on adjusted gross revenues

3.00%

Royalty payment period

3 years

Percentage of royalty payable in cash

50.00%

Percentage of royalty payable in common stock

50.00%

Payments to Acquire Real Estate

$ 5,000,000

Subsequent Event [Member] | EWSD [Member] | Secured Promissory Note [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 3,670,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Amortization period of Debt instrument

30 years

Debt instrument frequency payments of principal and interest | Installments

35

Subsequent Event [Member] | EWSD [Member] | Unsecured Promissory Note [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 830,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Amortization period of Debt instrument

30 years

Debt instrument frequency payments of principal and interest | Installments

35

Subsequent Event [Member] | Southwest [Member]

Subsequent Event [Line Items]

Area of real estate property | a

320